Sacubitril/valsartan vs. angiotensin receptor inhibition in heart failure: a real-world study in Taiwan.

In patients with HF with reduced ejection fraction, sacubitril/valsartan was superior to ARB therapy in reducing the occurrence of the primary outcome endpoint of hospitalization for worsening HF and cardiovascular death.